Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

ASTRAZENECA

(AZN)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

AstraZeneca : Results From Imfinzi Head and Neck Cancer Trial Negative

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/07/2018 | 02:31am EST

By Carlo Martuscelli

AstraZeneca PLC (AZN.LN) on Friday announced negative results from a phase 3 clinical trial of its cancer drug Imfinzi as a treatment for recurrent or metastatic head and neck squamous cell carcinoma.

The company said neither Imfinzi alone, nor Imfinzi plus add-on therapy tremelimumab, increased overall survival for treated patients when compared with standard-of-care chemotherapy, missing the primary objective in the Eagle trial. The patients enrolled in study had previously had their disease advance following platinum-based chemotherapy.

The Anglo-Swedish pharmaceutical said that while the results were disappointing, it remained committed to evaluating Imfinzi as a potential medicine for patients with head and neck cancer.

Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA 1.45% 764.7 Delayed Quote.13.51%
ASTRAZENECA 1.03% 6159 Delayed Quote.4.87%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTRAZENECA
02/23ASTRAZENECA : joins hands with Nasscom to set up accelerator healthcare programm..
AQ
02/14ASTRAZENECA : Up Over 9% After 4Q Revenue, Core EPS Beats -- Data Talk
DJ
02/14LONDON STOCK EXCHANGE : FTSE 100 squeezes out gains; ConvaTec drags midcaps
RE
02/14European shares give up three-month highs after shock U.S. data
RE
02/14LONDON MARKETS: London Stocks Cling To Gains; AstraZeneca Surges On Results
DJ
02/14ASTRAZENECA : Turns a Corner After a Decade of Struggles -- 3rd Update
DJ
02/14EUROPE MARKETS: Trade Optimism Helps European Stocks Shrug Off Growth Fears
DJ
02/14GLOBAL MARKETS LIVE : Google, Airbus, Volkswagen, Cisco…
02/14ASTRAZENECA : New cancer drugs, China give AstraZeneca welcome sales boost
RE
02/14ASTRAZENECA : Set for Growth in 2019 -- Earnings Review
DJ
More news
Financials ($)
Sales 2019 23 523 M
EBIT 2019 6 218 M
Net income 2019 2 766 M
Debt 2019 14 611 M
Yield 2019 3,47%
P/E ratio 2019 36,88
P/E ratio 2020 25,80
EV / Sales 2019 4,95x
EV / Sales 2020 4,50x
Capitalization 102 B
Chart ASTRAZENECA
Duration : Period :
AstraZeneca Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 82,0 $
Spread / Average Target 2,0%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Shriti Vadera Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA4.87%101 858
JOHNSON & JOHNSON5.85%363 785
PFIZER-3.46%249 168
ROCHE HOLDING LTD.13.89%238 335
NOVARTIS8.12%231 565
MERCK AND COMPANY5.71%210 032